Evidence map›Paper›PMID 29287241›Full record

ArticleTranslational oncology2018

Serine/Threonine Kinase CHEK1-Dependent Transcriptional Regulation of RAD54L Promotes Proliferation and Radio Resistance in Glioblastoma.

Xiaobin Bai, Jia Wang, Longwei Huo, Yuchen Xie, Wanfu Xie, Gaofeng Xu, Maode Wang

Open access · goldAbstract read
In one paragraph

Article in Translational oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Xiaobin BaiDepartment of Neurosurgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaaxin, China, 710061.
Jia WangDepartment of Neurosurgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaaxin, China, 710061.
Longwei HuoDepartment of Neurosurgery, The First Hospital of Yulin, Yulin, Shaanxi, China, 719000.
Yuchen XieSchool of Medicine, Xi'an Jiaotong University, Xi'an, Shaaxin, China, 710061.
Wanfu XieDepartment of Neurosurgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaaxin, China, 710061.
Gaofeng XuDepartment of Neurosurgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaaxin, China, 710061.
Maode WangDepartment of Neurosurgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaaxin, China, 710061. Electronic address: maodewang@163.com.
First Affiliated Hospital of Xi'an Jiaotong University · CNXi'an Jiaotong University · CNYulin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accumulating evidence indicates that Checkpoint kinase 1 (CHEK1) plays an essential role in tumor cells and that it could induce cell proliferation and could be related to prognosis in multiple types of cancer. However, the biological role and molecular mechanism of CHEK1 in GBM still remain unclear. In this study, we identified that CHEK1 expression was enriched in glioblastoma (GBM) tumors and was functionally required for tumor proliferation and that its expression was associated to poor prognosis in GBM patients. Mechanically, CHEK1 induced radio resistance in GBM cells, and CHEK1 knockdown increased cell apoptosis when combined with radiotherapy via regulation of the DNA repair/recombination protein 54L (RAD54L) expression. Therapeutically, we found that CHEK1 inhibitor attenuated tumor growth both in vitro and in vivo. Collectively, CHEK1 promotes proliferation, induces radio resistance in GBM, and could become a potential therapeutic target for GBM.

Identifiers

PMID29287241
PMCPMC6002345
OpenAlexW2776208190

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.